Vivian Cervantes's questions to Alpha Teknova Inc (TKNO) leadership • Q1 2025
Question
Vivian Cervantes inquired about the demand from cell and gene therapy customers following the recent FDA leadership change, any month-over-month improvements in the biotech funding landscape, and the dynamics of revenue per customer as new clients are onboarded.
Answer
President and CEO Stephen Gunstream stated it was too early to see an impact from the FDA leadership change but noted that the market remains challenging for early-stage biotechs. However, he affirmed that Teknova's key customers are executing their plans, supporting the company's 15% growth guidance for the custom biopharma segment. Gunstream also explained that while new, smaller customers can initially lower the average revenue per customer, the company still expects a 30-fold increase in spend as therapies progress from Phase I to commercialization.